388 related articles for article (PubMed ID: 31676303)
21. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Neal B; Perkovic V; Mahaffey KW; de Zeeuw D; Fulcher G; Erondu N; Shaw W; Law G; Desai M; Matthews DR;
N Engl J Med; 2017 Aug; 377(7):644-657. PubMed ID: 28605608
[TBL] [Abstract][Full Text] [Related]
22. Effect of Canagliflozin Compared With Sitagliptin on Serum Lipids in Patients with Type 2 Diabetes Mellitus and Heart Failure with Reduced Ejection Fraction: A Post-Hoc Analysis of the CANA-HF Study.
Dixon DL; Billingsley HE; Canada JM; Trankle CR; Kadariya D; Cooke R; Hart L; Van Tassell B; Abbate A; Carbone S
J Cardiovasc Pharmacol; 2021 Sep; 78(3):407-410. PubMed ID: 34132690
[TBL] [Abstract][Full Text] [Related]
23. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.
Neal B; Perkovic V; Matthews DR; Mahaffey KW; Fulcher G; Meininger G; Erondu N; Desai M; Shaw W; Vercruysse F; Yee J; Deng H; de Zeeuw D;
Diabetes Obes Metab; 2017 Mar; 19(3):387-393. PubMed ID: 28120497
[TBL] [Abstract][Full Text] [Related]
24. [Canaglifozin results in cardiovascular and renal protection in patients with type 2 diabetes : from CANVAS to CREDENCE].
Scheen AJ
Rev Med Liege; 2019 Oct; 74(10):508-513. PubMed ID: 31609553
[TBL] [Abstract][Full Text] [Related]
25. Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program.
Zhou Z; Jardine M; Perkovic V; Matthews DR; Mahaffey KW; de Zeeuw D; Fulcher G; Desai M; Oh R; Simpson R; Watts NB; Neal B
Diabetologia; 2019 Oct; 62(10):1854-1867. PubMed ID: 31399845
[TBL] [Abstract][Full Text] [Related]
26. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus.
Carbone S; Dixon DL
Cardiovasc Diabetol; 2019 May; 18(1):64. PubMed ID: 31138195
[TBL] [Abstract][Full Text] [Related]
27. Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial.
Sharma A; Razaghizad A; Joury A; Levin A; Bajaj HS; Mancini GBJ; Wong NC; Slee A; Ang FG; Rapattoni W; Neuen BL; Arnott C; Perkovic V; Mahaffey KW
J Am Heart Assoc; 2024 Feb; 13(3):e031586. PubMed ID: 38240199
[TBL] [Abstract][Full Text] [Related]
28. Effect of Canagliflozin on Heart Failure Hospitalization in Diabetes According to Baseline Heart Failure Risk.
Khan MS; Segar MW; Usman MS; Patel KV; Van Spall HGC; DeVore AD; Vaduganathan M; Lam CSP; Zannad F; Verma S; Butler J; Tang WHW; Pandey A
JACC Heart Fail; 2023 Jul; 11(7):825-835. PubMed ID: 37227388
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of action of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial.
Sen T; Koshino A; Neal B; Bijlsma MJ; Arnott C; Li J; Hansen MK; Ix JH; Heerspink HJL
Diabetes Obes Metab; 2022 Oct; 24(10):1950-1956. PubMed ID: 35635326
[TBL] [Abstract][Full Text] [Related]
30. Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials.
Tobe SW; Mavrakanas TA; Bajaj HS; Levin A; Tangri N; Slee A; Neuen BL; Perkovic V; Mahaffey KW; Rapattoni W; Ang FG
Diabetes Care; 2024 Mar; 47(3):501-507. PubMed ID: 38252809
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program.
Yu J; Arnott C; Neuen BL; Heersprink HL; Mahaffey KW; Cannon CP; Khan SS; Baldridge AS; Shah SJ; Huang Y; Li C; Figtree GA; Perkovic V; Jardine MJ; Neal B; Huffman MD
ESC Heart Fail; 2021 Apr; 8(2):1482-1493. PubMed ID: 33595905
[TBL] [Abstract][Full Text] [Related]
32. Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial.
Yu J; Li J; Leaver PJ; Arnott C; Huffman MD; Udell JA; Perkovic V; Mahaffey KW; de Zeeuw D; Fulcher G; Matthews DR; Shaw W; Rosenthal N; Neal B; Figtree GA
Cardiovasc Res; 2022 Mar; 118(4):1103-1114. PubMed ID: 33826709
[TBL] [Abstract][Full Text] [Related]
33. Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial.
Takashima H; Yoshida Y; Nagura C; Furukawa T; Tei R; Maruyama T; Maruyama N; Abe M
Diab Vasc Dis Res; 2018 Sep; 15(5):469-472. PubMed ID: 29923427
[TBL] [Abstract][Full Text] [Related]
34. Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.
Tanaka A; Inoue T; Kitakaze M; Oyama J; Sata M; Taguchi I; Shimizu W; Watada H; Tomiyama H; Ako J; Sakata Y; Anzai T; Uematsu M; Suzuki M; Eguchi K; Yamashina A; Saito Y; Sato Y; Ueda S; Murohara T; Node K
Cardiovasc Diabetol; 2016 Apr; 15():57. PubMed ID: 27044332
[TBL] [Abstract][Full Text] [Related]
35. Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial.
Tanaka A; Imai T; Shimabukuro M; Nakamura I; Matsunaga K; Ozaki Y; Minamino T; Sata M; Node K;
J Diabetes Investig; 2022 Dec; 13(12):1990-1999. PubMed ID: 36114704
[TBL] [Abstract][Full Text] [Related]
36. Treatment effect of canagliflozin for patients on therapy for heart failure: Pooled analysis of the CANVAS program and CREDENCE trial.
Jain SS; Yu J; Arnott C; Neal B; Perkovic V; Neuen BL; Jardine M; Mahaffey KW
Int J Cardiol; 2024 Jan; 395():131444. PubMed ID: 37844669
[TBL] [Abstract][Full Text] [Related]
37. Ethnic disparities in cardiovascular and renal responses to canagliflozin between Asian and White patients with type 2 diabetes mellitus: A post hoc analysis of the CANVAS Program.
Chen X; Hou X; Gao J; Yu X; Zeng W; Lv R; Yang X; Liu Y
Diabetes Obes Metab; 2024 Mar; 26(3):878-890. PubMed ID: 38031821
[TBL] [Abstract][Full Text] [Related]
38. Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial.
Sarraju A; Li J; Cannon CP; Chang TI; Agarwal R; Bakris G; Charytan DM; de Zeeuw D; Greene T; Heerspink HJL; Levin A; Neal B; Pollock C; Wheeler DC; Yavin Y; Zhang H; Zinman B; Perkovic V; Jardine M; Mahaffey KW
Am Heart J; 2021 Mar; 233():141-148. PubMed ID: 33358942
[TBL] [Abstract][Full Text] [Related]
39. Liver function markers predict cardiovascular and renal outcomes in the CANVAS Program.
Ferrannini G; Rosenthal N; Hansen MK; Ferrannini E
Cardiovasc Diabetol; 2022 Jul; 21(1):127. PubMed ID: 35787704
[TBL] [Abstract][Full Text] [Related]
40. Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial.
Sharma A; Marques P; Neuen BL; Fletcher RA; Slee A; Rapattoni W; Ang FG; Arnott C; Levin A; Verma S; Perkovic V; Mahaffey KW
Diabetes Obes Metab; 2024 Feb; 26(2):758-762. PubMed ID: 37881140
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
